Halozyme Therapeutics (HALO) Depreciation & Amortization (CF) (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $4.2 million in Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $4.2 million, up 55.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.9 million (up 21.74% YoY), and the FY2025 annual result was $11.4 million, up 10.57% from the prior year.
• Depreciation & Amortization (CF) advanced to $4.2 million in Q1 2026 per HALO's latest filing, from $3.3 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $4.2 million in Q1 2026 and troughed at $778000.0 in Q1 2022.
• A 5-year average of $2.6 million and a median of $2.7 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) jumped 237.02% in 2023, then decreased 8.47% in 2024.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $2.6 million in 2022, then climbed by 12.22% to $2.9 million in 2023, then fell by 6.35% to $2.7 million in 2024, then rose by 22.37% to $3.3 million in 2025, then grew by 27.12% to $4.2 million in 2026.
• Business Quant data shows HALO's Depreciation & Amortization (CF) at $4.2 million in Q1 2026, $3.3 million in Q4 2025, and $2.7 million in Q3 2025.